Genitourinary Cancers | Specialty

Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond

October 10th 2017

The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.

Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care

October 6th 2017

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors

October 6th 2017

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

October 6th 2017

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer

October 6th 2017

Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence

New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC

October 6th 2017

A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.

Chemotherapy Retains Vital Role in Bladder Cancer Care

October 6th 2017

Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.

Dr. Konety on Guidelines for the Management of Bladder Cancer

October 6th 2017

Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.

Dr. De Santis on the Future Treatment Landscape for Bladder Cancer

October 6th 2017

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma

October 5th 2017

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma

October 5th 2017

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

Advanced RCC Results Point to Potentially New Frontline Treatments

October 5th 2017

Michael R. Harrison, MD, discusses emerging data that are likely to impact the treatment landscape for patients with RCC.

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

October 4th 2017

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Atezolizumab + Bevacizumab in Treatment-Naive mRCC

October 4th 2017

Sunitinib Before Cytoreductive Nephrectomy in mRCC

October 4th 2017

CABOSUN: Upfront Use of Cabozantinib for mRCC

October 4th 2017

CheckMate-214: Nivolumab/Ipilimumab for mRCC?

October 4th 2017

Dr. Uzzo on Unmet Needs in Kidney Cancer

October 4th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.

Dr. Hoffman-Censits on Challenges With Sequencing for Urothelial Carcinoma

October 4th 2017

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

Phase III Data Show Benefit With Abiraterone in Castration-Sensitive Prostate Cancer

October 4th 2017

Tian Zhang, MD, discusses emerging results for patients with metastatic castration-sensitive prostate cancer.